MTIG is a coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.
The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources.
Through a ‘collective voice’ the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients.
Hervé Affagard, CEO of MaaT Pharma, said: “We are very proud to join the Microbiome Therapeutics Innovation Group as we share the group’s mission of advancing microbiome-based therapies to improve clinical outcomes for patients. We eagerly anticipate a productive and collaborative partnership with MTIG and its members to accelerate the transformation of fundamental research into market-ready microbiome innovations.”
Nikole Kimes, MTIG chairman and CEO of Siolta Therapeutics, added: “We are pleased to welcome MaaT Pharma to our diverse coalition of microbiome-based companies. Microbiome medicines hold great potential for the treatment of oncology diseases and Hervé Affagard’s team is dedicated to bringing therapies that improve survival in cancer.”
“We look forward to working alongside MaaT Pharma’s world-leading scientists as we seek to implement tangible policy solutions that accelerate the development and integration of life-saving FDA approved microbiome therapies into clinical practice.”
MTIG is now comprised of twelve microbiome therapeutics companies: Bacthera, BiomeSense, Bio-Me, Genetic Analysis, MaaT Pharma, Microba Life Sciences, Rebiotix, Inc., a Ferring Company, Seres Therapeutics, Servatus Biopharmaceuticals, Siolta Therapeutics, and Vedanta Biosciences.